OTC : BRRGF

BerGenBio ASA

$97.094 USD

$0 (0.0%)

Volume
37.3K
Average Volume
4.02K
Market Capitalization
$9.49B
P/E Ratio
-1.20
Dividend Yield
0.00%
Price Target
Year High
$97.09
Year Low
$0.03
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$3.23
Company Overview

OTC

Oystein Soug

Biotechnology

Healthcare

BRRGF

13

NO

USD

https://www.bergenbio.com

47 55 96 11 59

N/A

N/A

Liquidity Metrics

0.02

3.23

3.23

3.06

0.00

Sales & Valuation

$23.02M

23.35

0.87

-2.95

-84.20

Profitability

-$125.02

-$154.98M

-978.31%

-978.31%

-147.40%

-76.71%

P/E Metrics

-1.20

0.00

0.00

Analyst Price Target & Rating

N/A

0/5

2 Analysts

%

Financial Health Scores

2749.50

2/9

$66.93M

$86.75M

$19.75M

-$105.4M

Key Metrics (TTM)

$195.86M

12.19

-1.40

3.23

-147.40%

-96.10%

-125.94%

-34.40%

64 days

Company Executives
Name Title
Anne-Kirsti Aksnes Chief Clinical Officer
Kari Myren Chief Medical Officer
Ramzi Amri Chief Executive Officer
Oystein Soug Chief Executive Officer
Stian Brekke Head of Regulatory Affairs
Tore Kvam Chief Financial Officer
Anne Cecile Alvik Head of Quality Assurance & Employee Representative Director
Froydis Schulz Head of Health Safety & Environment
Gro Elisabeth Hjellum Chief Operating Officer
Kaja Tunhovd Johansen Head of Quality Control
Kristine Lofthus Chief Production Officer
Poll Results

No votes yet today — be the first to share your view!

About BerGenBio ASA (OTC:BRRGF) Stock

BerGenBio ASA is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapies for challenging conditions. This includes cancers that are immune-evasive, drug-resistant, or metastatic, as well as various respiratory diseases. Its leading drug candidate, Bemcentinib, is an orally available, small molecule AXL inhibitor that has progressed to Phase II clinical development. This involves studies across several significant cancer indications and for COVID-19. Specifically, its Phase II trials are focused on treating non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Another promising compound in its pipeline is tilvestamab, an anti-AXL antibody currently undergoing Phase Ib clinical evaluation. The company maintains a collabor ... ative agreement with Merck & Co. concerning its clinical trial initiatives. Founded in 2007, BerGenBio ASA is headquartered in Bergen, Norway.

Frequently Asked Questions

What is the current BerGenBio ASA (BRRGF) stock price?

BerGenBio ASA(OTC:BRRGF) stock price is $97.094 in the last trading session. During the trading session, BRRGF stock reached the peak price of $97.09404 while $0.025 was the lowest point it dropped to. The percentage change in BRRGF stock occurred in the recent session was 0.0% while the dollar amount for the price change in BRRGF stock was $0.

BRRGF's industry and sector of operation?

The OTC listed BRRGF is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of BRRGF?

Anne-Kirsti Aksnes | Chief Clinical Officer
Kari Myren | Chief Medical Officer
Ramzi Amri | Chief Executive Officer
Oystein Soug | Chief Executive Officer
Stian Brekke | Head of Regulatory Affairs

How many employees does BRRGF have?

Number of BRRGF employees currently stands at 13. BRRGF operates from Jonas Lies vei 91, Bergen, None 5009, NO.

Link for BRRGF official website?

Official Website of BRRGF is: https://www.bergenbio.com

How do I contact BRRGF?

BRRGF could be contacted at phone #47 55 96 11 59 and can also be accessed through its website. BRRGF operates from Jonas Lies vei 91, Bergen, None 5009, NO.

How many shares of BRRGF are traded daily?

The average number of BRRGF shares traded daily for last 3 months was 4.02K.

What is the market cap of BRRGF currently?

The market value of BRRGF currently stands at $9.49B with its latest stock price at $97.094